Bradmer Pharmaceuticals (TSE:GLX – Get Free Report) was upgraded by equities researchers at Benchmark to a “strong-buy” rating in a report released on Monday,Zacks.com reports.
Separately, Cantor Fitzgerald upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th.
Get Our Latest Analysis on GLX
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- How to Invest in Biotech Stocks
- First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
- Dividend Capture Strategy: What You Need to Know
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
